Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Zemaira | Alpha1-proteinase inhibitor (Human) | Severe Alpha1-proteinase inhibitor deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Epidiolex | cannabidiol | Seizures associated with Tuberous Sclerosis Complex (TSC) | Reimburse with clinical criteria and/or conditions | Active | ||
Mayzent | siponimod | Secondary progressive multiple sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Sensipar | Cinacalcet hydrochloride | Secondary hyper-parathyroidism in chronic kidney disease | Do not list | Complete | ||
Ryaltris | olopatadine hydrochloride and mometasone | Seasonal allergic rhinitis | Pending | |||
Dymista | Azelastine HCl and fluticasone propionate | Seasonal allergic rhinitis | Do not list | Complete | ||
Perseris | risperidone | Schizophrenia, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
TBC | risperidone | Schizophrenia, adults | Suspended | |||
Zeldox | Ziprasidone hydrochloride | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
Abilify | Aripiprazole | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete |